---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059024"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:28:21.143127+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Candel reports CAN-2409 phase 2 interim data: 71.4% survival at 36 months vs 16.7% in borderline PDAC

## Summary
- Estimated overall survival rate 71.4% at 24 & 36 months for CAN-2409 arm vs 16.7% control in borderline resectable PDAC.
- Median overall survival not yet reached in CAN-2409 arm; control arm median OS was 12.5 months.
- Robust immune activation: dense aggregates of CD8+ granzyme B+ T cells, dendritic cells, and B cells in tumor.
- No dose-limiting toxicities or pancreatitis reported; multiple injections generally well tolerated.
- 5 of 7 CAN-2409 patients alive at data cutoff; two survived >45 months. Control: 1 of 6 alive.

## SEC filing metadata
- accession: 0000950170-23-059024
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023059024/0000950170-23-059024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023059024/cadl-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059024
- JSON: https://secwatch.observer/filing/0000950170-23-059024.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.